Anne Rodallec (0000-0002-0787-8241)

Personal information

Biography

Anne Rodallec obtained her pharmaceutical degree and Ph.D in pharmacokinetics and oncology under the supervision at the pharmacy school of Aix-Marseille University, France. She is now an assistant teacher at the same faculty and her work focuses on the development of liposomes and immunoliposomes in cancer, from their formulation to the in vivo assays. She is currently evaluating the interest of combining these liposomes to immunotherapy and developing biomathematic models to determine the best treatment regimen.

Activities

Collapse all

Université d'Aix-Marseille: Marseille, FR

2020-09-01 to present | Assistant professor (Pharmacokinetics)

Employment

Anne Rodallec

https://orcid.org/0000-0002-0787-8241

Personal information

Emails & domains

Verified email domains

Websites & social links

Keywords

Biography

Activities

Employment (1)

Université d'Aix-Marseille: Marseille, FR

Education and qualifications (2)

Aix-Marseille University: Marseille, FR

Aix-Marseille University: Marseille, FR

Professional activities (1)

Controlled Release Society BeNeLux & France Local Chapter: marseille, FR

Funding (5)

COMPLICITY

COMPLICITY

COMPLICITY

NaonoImmuno

Development of a docetaxel-trastuzumab immunoliposome in breast cancer

Works (19)

Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models

Conditional generation of free radicals by selective activation of alkoxyamines: towards more effective and less toxic targeting of brain tumors

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic

Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer

Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)

Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors

Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles

Claramines: A New Class Of Broad‐Spectrum Antimicrobial Agents With Bimodal Activity

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase‐driven adaptive dosing of 5‐FU in patients with digestive cancer

Peer review (1 review for 1 publication/grant)